
    
      Study participants will receive 8 cycles of neoadjuvant study treatment and then will undergo
      surgery for their breast cancer. After surgery, participants will receive 9 cycles of study
      treatment and up to 10 years of variable endocrine therapy. Each cycle is 21 days long.
    
  